A ‘wonder drug’ that can stave off Alzheimer’s disease could delay the life-ruining symptoms for up to three years, striking new data shows.
Previous trials of donanemab have found that the benefits, which occur in 35 per cent of patients, only last for around four to seven months.
But a new study presented at the Alzheimer’s Association International Conference (AAIC) in London showed it not only postponed memory and thinking problems, but also protected against damage associated with the disease.
The treatment – delivered via infusion – has been licensed for use in the UK since 2024 but has not been made available on the NHS.
Health
To provide well-rounded coverage and a breadth of insight across various events, we rely on contributions from several staff writers, each bringing their own area of expertise to our publication.
